Josep Mallolas
University of Barcelona
188 Papers
1.8K Citations
Josep Mallolas is an academic researcher from University of Barcelona. The author has contributed to research in topics: Medicine & Viral load. The author has an hindex of 41, co-authored 162 publications.
Chat about Author
Papers
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
Juan Berenguer,Julio Álvarez-Pellicer,Pilar Miralles Martín,José López-Aldeguer,Miguel Angel Von‐Wichmann,Carmen Quereda,Josep Mallolas,José Sanz,Cristina Tural,José María Bellón,Juan González-García +10 more
TL;DR: It is suggested that the achievement of an SVR after interferon‐ribavirin therapy in patients coinfected with HIV/HCV reduces liver‐related complications and mortality.
324
Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial
Jürgen K. Rockstroh,Mark T. Nelson,Christine Katlama,J. Lalezari,Josep Mallolas,Mark Bloch,Gail V. Matthews,Michael S. Saag,Philippe J. Zamor,Chloe Orkin,Jacqueline Gress,Stephanie O. Klopfer,Melissa Shaughnessy,Janice Wahl,Bach-Yen Nguyen,Eliav Barr,Heather L. Platt,Michael N. Robertson,Mark S. Sulkowski +18 more
TL;DR: This HCV treatment regimen seems to be effective and well tolerated for patients co-infected with HIV with or without cirrhosis, and these data are consistent with previous trials of this regimen in the monoinfected population.
314
Overview of SARS-CoV-2 infection in adults living with HIV.
Juan Ambrosioni,Jose-Luis Blanco,Juliana Reyes-Urueña,Mary-Ann Davies,Omar Sued,Maria Angeles Marcos,Esteban Martínez,Silvia Bertagnolio,Silvia Bertagnolio,José Alcamí,José Alcamí,José M. Miró,José Luis Santiago Blanco,Lorena de la Mora,Felipe Garcia-Alcaide,Ana González-Cordón,Alexis Inciarte,Montserrat Laguno,Lorna Leal,Esteban Martínez-Chamorro,María Martínez-Rebollar,Jhon Rojas,Berta Torres,Josep Mallolas,Laia Albiac,Daiana L. Agöero,Marta Bodro,Celia Cardozo,Mariana Chumbita,Nicol García,Carolina Garcia-Vidal,Marta Hernández-Meneses,Sabina Herrera,Laura Linares,Antonio Moreno,Laura Morata,Jose A. Martínez-Martínez,Pedro Puerta,Verónica Rico,Alex Soriano,M. Martinez,Maria Mar Mosquera,Maria Angeles Marcos,Jordi Vila,Montse Tuset,Dolors Soy,Anna Vilella,Alex Almuedo,María J. Pinazo,Jose Muñoz +49 more
TL;DR: A review of the most relevant features of COVID-19 in people living with HIV and highlighted topics where further research is required is provided in this article, where the authors have reviewed the most salient features of the COVID19 pandemic and highlighted the areas where further work is needed.
206
Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count
Felipe García,Elisa de Lazzari,Montserrat Plana,Pedro Castro,Gabriel Mestre,Meritxell Nomdedeu,Emilio Fumero,Esteban Martínez,Josep Mallolas,José L. Blanco,José M. Miró,Tomás Pumarola,Teresa Gallart,José M. Gatell +13 more
TL;DR: It seems that the immune recovery slows down after approximately 3 years of HAART and reaches a plateau after 4–5 years ofHAART, while long-term immune recovery is possible regardless of baseline CD4+ T-cell count.
206
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial
Mark S. Sulkowski,Stanislas Pol,Josep Mallolas,Hugo Fainboim,Curtis Cooper,Jihad Slim,Antonio Rivero,Carmen Mak,Seth Thompson,Anita Y. M. Howe,Larissa Wenning,Peter Sklar,Janice Wahl,Wayne Greaves +13 more
TL;DR: Boceprevir in combination with peginterferon-ribavirin could be an important therapeutic option for patients with HCV and HIV.
185